Kiora Reports Phase 1 Study on KIO-101 Eye Inflammation Treatment

Kiora Pharmaceuticals, Inc., headquartered in Encinitas, California, has revealed findings from a Phase 1 double-blind study involving KIO-101, a strong, non-steroidal anti-inflammatory drug. This study, published in the journal Pharmaceutics, demonstrated that a 12-day regimen of KIO-101 eye drops was well tolerated among healthy volunteers and patients with ocular inflammation. Results indicated notable reductions in conjunctival hyperemia in the treatment group compared to the placebo group.

Kiora's proprietary formulation includes compounds like KIO-101, designed for topical application, and KIO-104, intended for intravitreal injections. These formulations aim to mitigate T-cell-induced inflammation specifically within the eye, avoiding the systemic side effects linked with conventional anti-inflammatory treatments.

Dr. Eric Daniels, Chief Development Officer at Kiora, highlighted the encouraging outcomes which underscore the molecule's potential for addressing ocular inflammation. Anticipated to commence later this year, a Phase 2 trial of KIO-104 will focus on treating posterior non-infectious uveitis, a severe inflammatory condition of the retina that can lead to vision loss. An alternative to existing treatments like steroid injections, KIO-104 presents a promising non-steroidal therapeutic option for various retinal inflammatory diseases.

The Phase 1 study encompassed a two-part, double-masked, placebo-controlled design. Part I included 24 healthy volunteers administered ascending doses of KIO-101, while Part II comprised 21 patients with conjunctival hyperemia, treated with either KIO-101 or a placebo. Key findings from the study revealed that KIO-101 was well tolerated, with no serious adverse events, and demonstrated a statistically significant decrease in conjunctival hyperemia compared to the placebo.

Kiora plans to advance to a Phase 2 trial for KIO-104, which will be administered intravitreally to target posterior non-infectious uveitis. This condition, an autoimmune disorder that inflames the retina and other parts of the eye, can lead to significant vision impairment.

Kiora Pharmaceuticals specializes in developing treatments for orphan retinal diseases. Their pipeline includes KIO-301 for retinitis pigmentosa, choroideremia, and Stargardt disease, along with KIO-104 targeting posterior non-infectious uveitis. These advancements signify Kiora's commitment to addressing challenging eye conditions with innovative therapeutic solutions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!